NAMs Technology Partn3Ring webinar series: Session 3

This is the third session in our Technology Partn3Ring webinar series focusing on new approach methodologies (NAMs) and will include presentations showcasing in vitro models to replace the use of animals in bone, liver, heart and lung assays. 

Speakers and topics

An MPS assay for human oral bioavailability: Seeking partners to accelerate assay validation 
Yassen Abbas (CN-Bio Innovations)

• CN-BIO Innovations develop microphysiological systems (MPS) models for drug discovery and development including liver, lung, multi-organ and immune competent models.
• Looking for partners to help further qualify the models across use cases with a particular focus on new drug modalities.

Precision in motion: Functional human models for the future of drug safety 
Erika Ferrari (BiomimX)

• BiomimX have developed uHeart, a model of functional beating human cardiac tissue for cardiotoxicity and safety testing.
• Seeking scientific partners to expand model validation (e.g. relevant cell providers) and partners to co-develop bespoke models for drug testing.

In vitro modelling of human osteoarthritis and tissue innervation
Abbas Ishaq (Alcyomics)

• Alcyomics have developed a human osteochondral ex vivo model, generated from primary mesenchymal stem cells with the ability to include innervation and induce an osteoarthritic disease phenotype.
• Looking for collaborators to further qualify their model, with the aim of establishing it as a robust translational platform for compound screening and therapeutic development.

Title TBC 
Vinit Pereira (ImmuONE)

• ImmuONE have developed morph_ONE, a high-content imaging-based safety screening tool designed to detect direct exposure and off-target toxicities in the lung.
• Seeking end users to apply morph_ONE as a Tier 1 lung safety screening approach, enabling early identification of direct exposure off-target toxicities.

About Technology Partn3Ring webinars

The NC3Rs Technology Partn3Ring webinars showcase technologies with 3Rs potential to the wider scientific community to identify new partners for further development and use. Open to researchers, clinicians, pharmaceutical and industry professionals, each webinar features short pitches outlining 3Rs research, tools and technologies. Attendees can ask questions and connect with the speakers to access unique collaboration opportunities.